Trading of Bio-Rad Laboratories was halted at 09:31 AM EST due to "LULD Pause".

Bio-Rad Laboratories (BIO.B) Competitors

$267.43 0.00 (0.00%)

As of 05/22/2026

BIO.B vs. VLTO, FTV, NVMI, RVTY, and CAMT

Should you buy Bio-Rad Laboratories stock or one of its competitors? MarketBeat compares Bio-Rad Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Rad Laboratories include Veralto (VLTO), Fortive (FTV), Nova (NVMI), Revvity (RVTY), and Camtek (CAMT). These companies are all part of the "measuring and control equipment" industry.

How does Bio-Rad Laboratories compare to Veralto?

Bio-Rad Laboratories (NYSE:BIO.B) and Veralto (NYSE:VLTO) are both measuring and control equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Veralto has a consensus price target of $105.88, suggesting a potential upside of 22.89%. Given Veralto's stronger consensus rating and higher probable upside, analysts plainly believe Veralto is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Veralto	0 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.45

Bio-Rad Laboratories has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Veralto has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 91.3% of Veralto shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 0.4% of Veralto shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Veralto has a net margin of 17.33% compared to Bio-Rad Laboratories' net margin of 6.52%. Veralto's return on equity of 34.63% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Veralto	17.33%	34.63%	13.44%

Veralto has higher revenue and earnings than Bio-Rad Laboratories. Veralto is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	2.77	$759.90M	$6.07	44.06
Veralto	$5.59B	3.78	$940M	$3.87	22.26

In the previous week, Veralto had 3 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 4 mentions for Veralto and 1 mentions for Bio-Rad Laboratories. Veralto's average media sentiment score of 0.13 beat Bio-Rad Laboratories' score of 0.00 indicating that Veralto is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veralto	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Veralto beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Fortive?

Bio-Rad Laboratories (NYSE:BIO.B) and Fortive (NYSE:FTV) are both measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Fortive has a net margin of 12.84% compared to Bio-Rad Laboratories' net margin of 6.52%. Fortive's return on equity of 12.66% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Fortive	12.84%	12.66%	6.98%

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 94.9% of Fortive shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 0.7% of Fortive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bio-Rad Laboratories has higher earnings, but lower revenue than Fortive. Fortive is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	2.77	$759.90M	$6.07	44.06
Fortive	$4.16B	4.43	$579.20M	$1.67	36.18

In the previous week, Fortive had 3 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 4 mentions for Fortive and 1 mentions for Bio-Rad Laboratories. Fortive's average media sentiment score of 1.24 beat Bio-Rad Laboratories' score of 0.00 indicating that Fortive is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortive	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortive has a consensus price target of $61.54, indicating a potential upside of 1.85%. Given Fortive's stronger consensus rating and higher probable upside, analysts plainly believe Fortive is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fortive	2 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.06

Bio-Rad Laboratories has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Fortive has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Summary

Fortive beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Nova?

Bio-Rad Laboratories (NYSE:BIO.B) and Nova (NASDAQ:NVMI) are both measuring and control equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Bio-Rad Laboratories has higher revenue and earnings than Nova. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Nova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	2.77	$759.90M	$6.07	44.06
Nova	$902.53M	18.49	$259.22M	$8.02	65.47

Bio-Rad Laboratories has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Nova has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

Nova has a net margin of 29.21% compared to Bio-Rad Laboratories' net margin of 6.52%. Nova's return on equity of 21.77% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Nova	29.21%	21.77%	12.56%

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 83.0% of Nova shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 1.0% of Nova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Nova had 9 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 10 mentions for Nova and 1 mentions for Bio-Rad Laboratories. Nova's average media sentiment score of 0.22 beat Bio-Rad Laboratories' score of 0.00 indicating that Nova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nova	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nova has a consensus target price of $518.22, indicating a potential downside of 1.30%. Given Nova's stronger consensus rating and higher possible upside, analysts clearly believe Nova is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nova	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Nova beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Revvity?

Bio-Rad Laboratories (NYSE:BIO.B) and Revvity (NYSE:RVTY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bio-Rad Laboratories has higher earnings, but lower revenue than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	2.77	$759.90M	$6.07	44.06
Revvity	$2.86B	3.80	$241.20M	$2.09	46.60

In the previous week, Revvity had 11 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 12 mentions for Revvity and 1 mentions for Bio-Rad Laboratories. Revvity's average media sentiment score of 0.35 beat Bio-Rad Laboratories' score of 0.00 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revvity	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bio-Rad Laboratories has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Revvity has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Revvity has a net margin of 8.26% compared to Bio-Rad Laboratories' net margin of 6.52%. Revvity's return on equity of 8.00% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Revvity	8.26%	8.00%	4.83%

Revvity has a consensus target price of $107.73, indicating a potential upside of 10.60%. Given Revvity's stronger consensus rating and higher possible upside, analysts clearly believe Revvity is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Revvity	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23

Summary

Revvity beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Camtek?

Camtek (NASDAQ:CAMT) and Bio-Rad Laboratories (NYSE:BIO.B) are both mid-cap measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Camtek has a net margin of 9.63% compared to Bio-Rad Laboratories' net margin of 6.52%. Camtek's return on equity of 22.26% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Camtek	9.63%	22.26%	11.70%
Bio-Rad Laboratories	6.52%	3.56%	2.49%

41.9% of Camtek shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 79.4% of Camtek shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Camtek has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Bio-Rad Laboratories has higher revenue and earnings than Camtek. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Camtek, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Camtek	$496.07M	15.78	$50.72M	$0.87	196.39
Bio-Rad Laboratories	$2.58B	2.77	$759.90M	$6.07	44.06

In the previous week, Bio-Rad Laboratories had 1 more articles in the media than Camtek. MarketBeat recorded 1 mentions for Bio-Rad Laboratories and 0 mentions for Camtek. Camtek's average media sentiment score of 0.53 beat Bio-Rad Laboratories' score of 0.00 indicating that Camtek is being referred to more favorably in the media.

Company	Overall Sentiment
Camtek	Positive
Bio-Rad Laboratories	Neutral

Camtek presently has a consensus target price of $174.33, indicating a potential upside of 2.03%. Given Camtek's stronger consensus rating and higher probable upside, analysts clearly believe Camtek is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Camtek	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Camtek beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIO.B vs. The Competition

Export

Metric	Bio-Rad Laboratories	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$7.16B	$3.40B	$6.40B	$23.26B
Dividend Yield	N/A	2.26%	2.76%	4.09%
P/E Ratio	44.06	18.96	20.83	31.04
Price / Sales	2.77	197.17	532.32	81.45
Price / Cash	26.68	125.17	43.49	25.06
Price / Book	1.04	7.21	10.49	4.80
Net Income	$759.90M	$24.25M	$3.56B	$1.07B
7 Day Performance	N/A	5.27%	3.03%	2.04%
1 Month Performance	-10.69%	4.39%	2.62%	1.60%
1 Year Performance	6.94%	67.15%	36.84%	27.18%

Bio-Rad Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIO.B Bio-Rad Laboratories	N/A	$267.43 flat	N/A	+6.9%	$7.16B	$2.58B	44.06	8,200
VLTO Veralto	4.4451 of 5 stars	$85.90 -0.3%	$105.88 +23.3%	-14.3%	$21.10B	$5.50B	22.20	17,000
FTV Fortive	3.3833 of 5 stars	$59.06 +0.0%	$61.54 +4.2%	-13.5%	$18.00B	$4.16B	35.36	10,000	Positive News
NVMI Nova	3.2527 of 5 stars	$496.50 +0.5%	$518.22 +4.4%	+188.1%	$15.78B	$902.53M	61.91	1,612	Gap Up
RVTY Revvity	2.8163 of 5 stars	$95.41 +0.6%	$107.73 +12.9%	+8.1%	$10.64B	$2.86B	45.65	11,000	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BIO.B) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Rad Laboratories (BIO.B) Competitors

BIO.B vs. VLTO, FTV, NVMI, RVTY, and CAMT

How does Bio-Rad Laboratories compare to Veralto?

Summary

How does Bio-Rad Laboratories compare to Fortive?

Summary

How does Bio-Rad Laboratories compare to Nova?

Summary

How does Bio-Rad Laboratories compare to Revvity?

Summary

How does Bio-Rad Laboratories compare to Camtek?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO.B vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Rad Laboratories (BIO.B) Competitors

BIO.B vs. VLTO, FTV, NVMI, RVTY, and CAMT

How does Bio-Rad Laboratories compare to Veralto?

Do analysts recommend BIO.B or VLTO?

Which has more risk and volatility, BIO.B or VLTO?

Do institutionals & insiders hold more shares of BIO.B or VLTO?

Is BIO.B or VLTO more profitable?

Which has higher earnings & valuation, BIO.B or VLTO?

Does the media favor BIO.B or VLTO?

Summary

How does Bio-Rad Laboratories compare to Fortive?

Is BIO.B or FTV more profitable?

Do institutionals and insiders believe in BIO.B or FTV?

Which has higher valuation & earnings, BIO.B or FTV?

Does the media favor BIO.B or FTV?

Do analysts prefer BIO.B or FTV?

Which has more risk & volatility, BIO.B or FTV?

Summary

How does Bio-Rad Laboratories compare to Nova?

Which has stronger valuation & earnings, BIO.B or NVMI?

Which has more volatility & risk, BIO.B or NVMI?

Is BIO.B or NVMI more profitable?

Do insiders & institutionals believe in BIO.B or NVMI?

Does the media favor BIO.B or NVMI?

Do analysts recommend BIO.B or NVMI?

Summary

How does Bio-Rad Laboratories compare to Revvity?

Do institutionals & insiders hold more shares of BIO.B or RVTY?

Which has higher valuation & earnings, BIO.B or RVTY?

Does the media prefer BIO.B or RVTY?

Which has more volatility and risk, BIO.B or RVTY?

Is BIO.B or RVTY more profitable?

Do analysts recommend BIO.B or RVTY?

Summary

How does Bio-Rad Laboratories compare to Camtek?

Is CAMT or BIO.B more profitable?

Do insiders & institutionals have more ownership in CAMT or BIO.B?

Which has more risk and volatility, CAMT or BIO.B?

Which has higher earnings & valuation, CAMT or BIO.B?

Does the media refer more to CAMT or BIO.B?

Do analysts recommend CAMT or BIO.B?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO.B vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools